tiprankstipranks
Advertisement
Advertisement

ATYR Stock Latest News

aTyr Pharma reports Q2 EPS (11c), consensus (13c)
The FlyaTyr Pharma reports Q2 EPS (11c), consensus (13c)
12h ago
ATYR
aTyr Pharma announces restructuring, will lay off roughly 60% of workforce
PremiumThe Fly
aTyr Pharma announces restructuring, will lay off roughly 60% of workforce
12h ago
ATYR
aTyr Pharma Regains Global Rights to Efzofitimod
PremiumCompany Announcements
aTyr Pharma Regains Global Rights to Efzofitimod
7d ago
8K
ATYR
aTyr Pharma Lawsuit: Company Asks Court to Dismiss Investor Securities Claims 
PremiumClass Action
aTyr Pharma Lawsuit: Company Asks Court to Dismiss Investor Securities Claims 
11d ago
ATYR
Joseph Pantginis Reiterates Hold as Efzofitimod Shifts to Restrictive Lung Phenotype After Mixed Phase 3 EFZO-FIT Results
PremiumRatings
Joseph Pantginis Reiterates Hold as Efzofitimod Shifts to Restrictive Lung Phenotype After Mixed Phase 3 EFZO-FIT Results
23d ago
ATYR
aTyr Pharma Granted Nasdaq Extension to Regain Compliance
PremiumCompany AnnouncementsaTyr Pharma Granted Nasdaq Extension to Regain Compliance
2M ago
8K
ATYR
Phase 3 Efzofitimod Readout Nears: What ATYR Investors Should Watch in Pulmonary Sarcoidosis
Premium
Company Announcements
Phase 3 Efzofitimod Readout Nears: What ATYR Investors Should Watch in Pulmonary Sarcoidosis
2M ago
ATYR
aTyr Pharma Refines Efzofitimod Strategy After Phase 2 Data
Premium
Company Announcements
aTyr Pharma Refines Efzofitimod Strategy After Phase 2 Data
2M ago
8K
ATYR
aTyr Pharma upgraded to Buy from Hold at Freedom Broker
PremiumThe Fly
aTyr Pharma upgraded to Buy from Hold at Freedom Broker
3M ago
ATYR
aTyr Pharma Inc options imply 30.5% move in share price post-earnings
PremiumThe Fly
aTyr Pharma Inc options imply 30.5% move in share price post-earnings
3M ago
ATYR
Midday Fly By: Applied Materials, Figma post ‘beat and raise’ reports
PremiumThe Fly
Midday Fly By: Applied Materials, Figma post ‘beat and raise’ reports
3M ago
BX
DLO
aTyr Pharma reports Q1 EPS (11c), consensus (15c)
PremiumThe Fly
aTyr Pharma reports Q1 EPS (11c), consensus (15c)
3M ago
ATYR
Boris Peaker Reiterates Hold as Constructive FDA Pathway Is Offset by Long Timelines and Funding Overhang for Efzofitimod Sarcoidosis Program
PremiumRatingsBoris Peaker Reiterates Hold as Constructive FDA Pathway Is Offset by Long Timelines and Funding Overhang for Efzofitimod Sarcoidosis Program
3M ago
ATYR
Joseph Pantginis Reiterates Hold Rating as FDA Feedback Refocuses Phase 3 Trial Despite Prior Endpoint Miss
Premium
Ratings
Joseph Pantginis Reiterates Hold Rating as FDA Feedback Refocuses Phase 3 Trial Despite Prior Endpoint Miss
3M ago
ATYR
aTyr Pharma provides regulatory update on efzofitimod following Type C meeting
Premium
The Fly
aTyr Pharma provides regulatory update on efzofitimod following Type C meeting
3M ago
ATYR
aTyr Pharma Announces New Phase 3 Sarcoidosis Trial
PremiumCompany Announcements
aTyr Pharma Announces New Phase 3 Sarcoidosis Trial
3M ago
8K
ATYR
ATYR Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
ATYR Upcoming Earnings Report: What to Expect?
3M ago
ATYR
aTyr Pharma Inc options imply 14.1% move in share price post-earnings
PremiumThe Fly
aTyr Pharma Inc options imply 14.1% move in share price post-earnings
3M ago
ATYR
Atyr Pharma Faces Nasdaq Delisting Risk After Minimum Bid Price Violation
PremiumCompany Announcements
Atyr Pharma Faces Nasdaq Delisting Risk After Minimum Bid Price Violation
5M ago
ATYR
aTyr Pharma reports Q4 EPS (14c), consensus (17c)
PremiumThe FlyaTyr Pharma reports Q4 EPS (14c), consensus (17c)
5M ago
ATYR
aTyr Pharma announces U.S. FDA accepted meeting request for efzofitimod
Premium
The Fly
aTyr Pharma announces U.S. FDA accepted meeting request for efzofitimod
6M ago
ATYR
aTyr Pharma Receives Nasdaq Deficiency Notice
Premium
Company Announcements
aTyr Pharma Receives Nasdaq Deficiency Notice
8M ago
8K
ATYR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >